PZ0191
克唑替尼
≥98% (HPLC), c-Met (hepatocyte growth factor receptor) inhibitor, powder
别名:
PF 2341066, PF-02341066, PF02341066, 克唑替尼, （R）-3-[1-（2,6-二氯-3-氟 - 苯基）-乙氧基]-5-（1-哌啶-4-基-1H-吡唑-4-基）-吡啶-2-基胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H22Cl2FN5O
化学文摘社编号:
分子量:
450.34
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
克唑替尼, ≥98% (HPLC)
SMILES string
C[C@@H](Oc1cc(cnc1N)-c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl
InChI
1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
InChI key
KTEIFNKAUNYNJU-GFCCVEGCSA-N
assay
≥98% (HPLC)
form
powder
color
white to tan
storage temp.
room temp
Quality Level
Application
克唑替尼已被用于：
- 研究其对肝细胞生长因子受体（c-Met）表达、增殖和凋亡的影响
- 阻断上皮细胞中神经营养性酪氨酸激酶1型受体（NTRK1）的活性
- 恢复对厄洛替尼的敏感性
Biochem/physiol Actions
ATP 竞争性 c-MET/ALK 抑制剂
克唑替尼（PF-02341066）是受体酪氨酸激酶（RTKs）c-Met（肝细胞生长因子受体）和间变性淋巴瘤激酶（ALK）的 ATP 竞争性抑制剂。在 > 120 种研究过的不同的 RTK 中，克唑替尼是一种高度特异性的 c-Met 和 ALK 抑制剂。克里唑蒂尼被批准用于治疗具有 ALK 融合突变的非小细胞肺癌（NSCLC）亚型。
Features and Benefits
这种化合物是激酶磷酸酶生物学研究的特色产品。点击此处发现更多特色激酶磷酸酶生物产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。
signalword
Warning
hcodes
Hazard Classifications
Aquatic Acute 1 - Eye Irrit. 2 - Muta. 2 - Skin Sens. 1
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
Greenfield E, et al.
eLife, 3, e04037-e04037 (2014)
PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells
Chen C, et al.
Experimental and Therapeutic Medicine, 15(5), 4543-4549 (2018)
Shota Yamamoto et al.
Radiology, 272(2), 568-576 (2014-06-03)
To present a radiogenomic computed tomographic (CT) characterization of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) (ALK+). In this HIPAA-compliant institutional review board-approved retrospective study, CT studies, ALK status, and clinical-pathologic data in 172 patients with NSCLC from
Zheng Liu et al.
Oncoimmunology, 9(1), 1758003-1758003 (2020-09-15)
Despite some of the oncogenic driver mutations that have been associated with increased expression of programmed death-ligand 1 (PD-L1), the correlation between PD-L1 expression and ROS1 fusion in NSCLC cells, especially for those with Crizotinib resistance has not been fully
Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation
Rochman M, et al.
Mucosal Immunology, 8(4), 785-785 (2015)
商品
Discover Bioactive Small Molecules for Kinase Phosphatase Biology
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持